XML 22 R43.htm IDEA: XBRL DOCUMENT v3.3.0.814
Segments of Business and Geographic Areas (Details 1) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 27, 2015
Jun. 28, 2015
Sep. 28, 2014
Sep. 27, 2015
Sep. 28, 2014
Segment Reporting Information [Line Items]          
Net gain on sale of assets/businesses       $ 1,274 $ 2,336
Asset write-downs       $ 367 259
Percentage Change in Operating Income Loss (39.50%)     (13.60%)  
Earnings before provision for taxes on income $ 4,122   $ 6,810 $ 15,438 17,860
Consumer          
Segment Reporting Information [Line Items]          
Net gain on sale of assets/businesses 229     229 $ 388
Pharmaceutical          
Segment Reporting Information [Line Items]          
Net gain on sale of assets/businesses   $ 981   981
Other Expenses     $ 220   $ 220
Litigation Expense     136
Medical Devices          
Segment Reporting Information [Line Items]          
Net gain on sale of assets/businesses     $ 1,948   $ 1,948
Litigation Expense 409   225   501
Asset write-downs 300     300  
Integration costs related to a business acquisition     167 113 429
Product Liability Accrual, Period Expense     $ 126 148 $ 126
Corporate and Other          
Segment Reporting Information [Line Items]          
Litigation Expense      
Operating Segments [Member]          
Segment Reporting Information [Line Items]          
Total Segment Operating Income $ 4,378   $ 7,053 $ 16,228 $ 18,578
Percentage Change in Operating Income Loss (37.90%)     (12.60%)  
Operating Segments [Member] | Consumer          
Segment Reporting Information [Line Items]          
Total Segment Operating Income [1] $ 811   407 $ 1,772 1,588
Percentage Change in Operating Income Loss 99.30%     11.60%  
Operating Segments [Member] | Pharmaceutical          
Segment Reporting Information [Line Items]          
Total Segment Operating Income [2] $ 2,732   3,247 $ 9,816 9,921
Percentage Change in Operating Income Loss (15.90%)     (1.10%)  
Operating Segments [Member] | Medical Devices          
Segment Reporting Information [Line Items]          
Total Segment Operating Income [3] $ 835   3,399 $ 4,640 7,069
Percentage Change in Operating Income Loss (75.40%)     (34.40%)  
Corporate, Non-Segment [Member]          
Segment Reporting Information [Line Items]          
Total Segment Operating Income [4] $ 256   $ 243 $ 790 $ 718
[1] Includes a gain of $229 million from the divestiture of the SPLENDA® brand recorded in the fiscal third quarter and fiscal nine months of 2015. Includes a gain of $388 million from the divestiture of the K-Y® brand recorded in the fiscal nine months of 2014.
[2] Includes litigation expense of $136 million in the fiscal nine months of 2015. Includes a gain of $981 million recorded in the fiscal nine months of 2015 from the divestiture of the U.S. license rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol extended-release tablets), and NUCYNTA® (tapentadol) oral solution. Includes an additional year of the Branded Prescription Drug Fee of $220 million recorded in the fiscal third quarter and fiscal nine months of 2014.
[3] Includes litigation expense of $409 million related to product liability and a $0.3 billion intangible asset write-down related to Acclarent recorded in the fiscal third quarter of 2015. Includes a net gain of $1,948 million from the divestiture of the Ortho-Clinical Diagnostics business, litigation expense of $225 million, Synthes integration costs of $167 million and $126 million for costs associated with the DePuy ASRTM Hip program recorded in the fiscal third quarter of 2014. Includes $148 million for costs associated with the DePuy ASRTM Hip program, Synthes integration costs of $113 million and a $0.3 billion intangible asset write-down related to Acclarent recorded in the fiscal nine months of 2015. Includes a net gain of $1,948 million from the divestiture of the Ortho-Clinical Diagnostics business, litigation expense of $501 million, Synthes integration costs of $429 million and $126 million for costs associated with the DePuy ASRTM Hip program recorded in the fiscal nine months of 2014.
[4] Amounts not allocated to segments include interest income/expense and general corporate income/expense.